abemaciclib — CareFirst (Caremark)

Initial criteria

• Member has recurrent or metastatic endometrial carcinoma with estrogen receptor positive tumors
• Requested medication is used in combination with letrozole

Reauthorization criteria

• No evidence of unacceptable toxicity or disease progression while on the current regimen

Approval duration

12 months